Skip to main content

COVID-19 trial protocols

Research into COVID-19 is exploding, as it needs to, and this includes randomised trials.  Between 23rd of January and 8th March 2020 there were 382 registered COVID-19 trials. Almost all of those were in China but the virus is now global and trials will move with it.

Researchers need to know about these trials, and they need to know quickly.  

Trials are therefore implementing a new, simplified process for handling COVID-19 trial protocols which is must faster and much simpler for authors. Please visit trialsjournal.biomedcentral.com/covid-19 for more information.

Page 1 of 4

  1. The 2019 coronavirus disease (COVID-19) pandemic continues to spread and affects large numbers of people with unprecedented impacts. Experimental evidence has already been obtained for use of the standardized ...

    Authors: Marcelo Augusto Duarte Silveira, Sergio Pinto de Souza, Erica Batista dos Santos Galvão, Maurício Brito Teixeira, Marcel Miranda Dantas Gomes, Lucas Petri Damiani, Bruno Andrade Bahiense, Julia Barros Cabral, Cicero Wandson Luiz Macedo De Oliveira, Talita Rocha Mascarenhas, Priscila Carvalho Guedes Pinheiro, Milena Souza Alves, Rodrigo Morel Vieira de Melo, Andresa Aparecida Berretta, Flávia Mendes Leite, Carolina Kymie Vasques Nonaka…
    Citation: Trials 2022 23:255
  2. The coronavirus disease 19 (COVID-19) pandemic has caused millions of deaths, and new treatments are urgently needed. Factors associated with a worse COVID-19 prognosis include old age (> 65 years), ethnicity,...

    Authors: Fabienne Jaun, Maria Boesing, Giorgia Lüthi-Corridori, Kristin Abig, Anja Makhdoomi, Nando Bloch, Christina Lins, Andrea Raess, Victoria Grillmayr, Philippe Haas, Philipp Schuetz, Luca Gabutti, Jürgen Muser, Anne B. Leuppi-Taegtmeyer, Stéphanie Giezendanner, Michael Brändle…
    Citation: Trials 2022 23:114
  3. To achieve higher effectiveness in population-based SARS-CoV-2 surveillance and to reliably predict the course of an outbreak, screening, and monitoring of infected individuals without major symptoms (about 40...

    Authors: Andreas Deckert, Simon Anders, Manuela De Allegri, Hoa Thi Nguyen, Aurélia Souares, Shannon McMahon, Matthias Meurer, Robin Burk, Matthias Sand, Lisa Koeppel, Lena Maier Hein, Tobias Roß, Tim Adler, Tobias Siems, Lucia Brugnara, Stephan Brenner…
    Citation: Trials 2021 22:656

    The Letter to this article has been published in Trials 2021 22:39

  4. Vaccine hesitancy is a major hurdle for stopping the COVID-19 pandemic. Recently, fear of vaccine side effects created widespread concern and paused global vaccination efforts. Many studies find that how medic...

    Authors: Nikkil Sudharsanan, Caterina Favaretti, Violetta Hachaturyan, Till Bärnighausen and Alain Vandormael
    Citation: Trials 2021 22:592
  5. The study objective is to quantify the effectiveness of ivermectin (subcutaneous/oral IVM) in the presence or absence of zinc (Zn) for clinical and radiological improvement in coronavirus disease 2019 (COVID-1...

    Authors: Shoaib Ashraf, Sohaib Ashraf, Iqra Farooq, Sidra Ashraf, Moneeb Ashraf, Muhammad Ahmad Imran, Larab Kalsoom, Rutaba Akmal, Muhammad Ghufran, Sundas Rafique, Muhammad Kiwan Akram, Zaigham Habib, Uzma Nasim Siddiqui, Ammara Ahmad, Shahroze Arshad, Muhammad Abdul Rehman Virk…
    Citation: Trials 2021 22:591
  6. There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate...

    Authors: Elena Bustamante Estebanez, Lucía Lavín Alconero, Beatriz Josa Fernández, Monica Gozalo Marguello, Juan Carlos López Caro, Jonathan Diez Vallejo, Marta Fernandez Sampedro, Pedro Muñoz Cacho, Carlos Richard Espiga and María Mar García Saiz
    Citation: Trials 2021 22:590
  7. The primary objective of the study is to demonstrate the efficacy of low-dose IFN-β in reducing the risk of SARS-CoV-2 recently infected elderly patients to progress towards severe COVID-19 versus control group w...

    Authors: Eleonora Aricò, Luciano Castiello, Laura Bracci, Francesca Urbani, Flavia Lombardo, Ilaria Bacigalupo, Antonio Ancidoni, Nicola Vanacore, Alessandro Falcione, Chiara Reggiani, Giovanni Marco Dutti, Maria Grazia Maglie, Ombretta Papa, Pier Luigi Bartoletti, Giuseppina Ozzella, Nazario Bevilacqua…
    Citation: Trials 2021 22:584
  8. SARS-CoV-2 binds to membrane-bound angiotensin-converting enzyme 2 (ACE2) which may result in downregulation of membrane-bound ACE2. ACE2 is a key regulator of the renin-angiotensin system (RAS) and is respons...

    Authors: Carinna Hockham, Sradha Kotwal, Arlen Wilcox, Abhinav Bassi, James McGree, Carol Pollock, Louise M. Burrell, Nikita Bathla, Mallikarjuna Kunigari, Vinay Rathore, Michael John, Enmoore Lin, Christine Jenkins, Angus Ritchie, Andrew McLachlan, Thomas Snelling…
    Citation: Trials 2021 22:573

    The Study protocol to this article has been published in Trials 2022 23:361

  9. The primary objective is to evaluate the efficacy of camostat to prevent respiratory deterioration in patients with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.

    Authors: Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie and Kevin Dhaliwal
    Citation: Trials 2021 22:550

    The Correction to this article has been published in Trials 2022 23:336

  10. The current randomized controlled trial (RCT) will be conducted to assess the effect of green tea intake on disease symptoms and laboratory parameters including C-reactive protein (CRP), erythrocyte sedimentat...

    Authors: Sara Mahmoodi, Mojtaba Yousefi, Omid Sadeghi, Ali Mahmoodabadi, Mohammadreza Sadriirani, Zahra Hosseinzade, Abdolhossein Jahanbakhsh, Seyed Bahman Panahande, Zaker Saeedinejad, Jan Mohamad Malekzadeh, Mohsen Naghmachi and Azizollah Pourmahmoudi
    Citation: Trials 2021 22:514
  11. Currently, coronavirus disease-2019 (COVID-19) is continuously and rapidly circulating, resulting in serious and extensive effects on human health. Due to the absence of antiviral medicine for COVID-19 thus fa...

    Authors: Wen Zhang, Qin Xie, Xiaoming Xu, Shuting Sun, Tian Fan, Xinxin Wu, Yao Qu, Jinhua Che, Tingrong Huang, Huacheng Li, You Zheng, Chao Jiang, Bangjiang Fang and Shuang Zhou
    Citation: Trials 2021 22:476
  12. The pathophysiology of SARS-Cov-2 is characterized by inflammation, immune dysregulation, coagulopathy, and endothelial dysfunction. No single therapeutic agent can target all these pathophysiologic substrates...

    Authors: Ambudhar Sharma, Charu Sharma, Sujeet Raina, Balraj Singh, Devendra Singh Dadhwal, Vinay Dogra, Swatantra Gupta, Shyam Bhandari and Vivek Sood
    Citation: Trials 2021 22:451
  13. To evaluate the effect of recombinant erythropoietin on hospitalised COVID-19 patients.

    Authors: Hamid Reza Samimagham, Mehdi Hassani Azad, Dariush Hooshyar, Maryam Haddad, Mohsen Arabi and Mitra KazemiJahromi
    Citation: Trials 2021 22:435
  14. This study aims to investigate the efficacy of curcumin-piperine co-supplementation on oxidative stress factors, clinical symptoms, and mortality rate in patients with coronavirus (COVID-19) admitted to the in...

    Authors: Gholamreza Askari, Babak Alikiaii, Davood Soleimani, Amirhossein Sahebkar, Mahdiye Mirjalili, Awat Feizi, Bijan Iraj and Mohammad Bagherniya
    Citation: Trials 2021 22:434
  15. It is currently thought that most—but not all—individuals infected with SARS-CoV-2 develop symptoms, but that the infectious period starts on average two days before the first overt symptoms appear. It is esti...

    Authors: Timo B. Brakenhoff, Billy Franks, Brianna Mae Goodale, Janneke van de Wijgert, Santiago Montes, Duco Veen, Eskild K. Fredslund, Theo Rispens, Lorenz Risch, Ariel V. Dowling, Amos A. Folarin, Patricia Bruijning, Richard Dobson, Tessa Heikamp, Paul Klaver, Maureen Cronin…
    Citation: Trials 2021 22:412

    The Update to this article has been published in Trials 2021 22:694

  16. The primary objective is to evaluate the comparative effectiveness of COVID-19 specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) Emergency Use Authorization (EUA), alongside UPMC...

    Authors: David T. Huang, Erin K. McCreary, J. Ryan Bariola, Richard J. Wadas, Kevin E. Kip, Oscar C. Marroquin, Stephen Koscumb, Kevin Collins, Judith A. Shovel, Mark Schmidhofer, Mary Kay Wisniewski, Colleen Sullivan, Donald M. Yealy, Meredith Axe, David A. Nace, Ghady Haidar…
    Citation: Trials 2021 22:363
  17. Currently, there are no approved treatments for early disease stages of COVID-19 and few strategies to prevent disease progression after infection with SARS-CoV-2. The objective of this study is to evaluate th...

    Authors: Verena Keitel, Björn Jensen, Torsten Feldt, Johannes C. Fischer, Johannes G. Bode, Christiane Matuschek, Edwin Bölke, Wilfried Budach, Christian Plettenberg, Kathrin Scheckenbach, Detlef Kindgen-Milles, Jörg Timm, Lisa Müller, Henrike Kolbe, Andreas Stöhr, Christian Calles…
    Citation: Trials 2021 22:343
  18. The general objective of this study is to test the hypothesis that administration of convalescent plasma from donors with previous diagnosis of severe COVID-19 pneumonia is safe and associated with a decrease ...

    Authors: Alonso Soto, Fiorella Krapp, Alex Vargas, Lucía Cabrejos, Enrique Argumanis, Patricia L. García, Karina Altamirano, Martín Montes, Pamela R. Chacón-Uscamaita and Patricia J. García
    Citation: Trials 2021 22:342
  19. Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is w...

    Authors: Philippe Bégin, Jeannie Callum, Nancy M. Heddle, Richard Cook, Michelle P. Zeller, Alan Tinmouth, Dean A. Fergusson, Melissa M. Cushing, Marshall J. Glesby, Michaël Chassé, Dana V. Devine, Nancy Robitalle, Renée Bazin, Nadine Shehata, Andrés Finzi, Allison McGeer…
    Citation: Trials 2021 22:323
  20. Uptake of vaccination against COVID-19 is key to controlling the pandemic. However, a significant proportion of people report that they do not intend to have a vaccine, often because of concerns they have abou...

    Authors: Ben Young, Marie Kotzur, Lauren Gatting, Carissa Bonner, Julie Ayre, Alex McConnachie, Carys Batcup, Kirsten McCaffery, Ronan O’Carroll and Kathryn A. Robb
    Citation: Trials 2021 22:311
  21. This research aims to study the efficacy of tannins co-supplementation on disease duration, severity and clinical symptoms, microbiota composition and inflammatory mediators in SARS-CoV2 patients.

    Authors: Silvia Molino, Andrea Pisarevsky, Fabiana Lopez Mingorance, Patricia Vega, Juan Pablo Stefanolo, Julieta Repetti, Guillermina Ludueña, Pablo Pepa, Juan Ignacio Olmos, Marcelo Rodriguez Fermepin, Tatiana Uehara, Sonia Villapol, Tor Savidge, Todd Treangen, Elisa Viciani, Andrea Castagnetti…
    Citation: Trials 2021 22:310
  22. The aim of this trial is to evaluate the antiviral efficacy, clinical efficacy, and safety of nelfinavir in patients with asymptomatic and mild COVID-19.

    Authors: Naoki Hosogaya, Taiga Miyazaki, Yuri Fukushige, Sachiko Takemori, Shinpei Morimoto, Hiroshi Yamamoto, Makoto Hori, Tomoya Kurokawa, Yohei Kawasaki, Michiko Hanawa, Yasuhisa Fujii, Hideki Hanaoka, Shingo Iwami, Koichi Watashi, Satoshi Yamagoe, Yoshitsugu Miyazaki…
    Citation: Trials 2021 22:309
  23. The primary objective is to demonstrate that, in patients with PCR-confirmed SARS-CoV-2 resulting in Acute Respiratory Distress Syndrome (ARDS), administration of 120mg/kg of body weight of intravenous Prolast...

    Authors: Natalie L. McEvoy, Jennifer L. Clarke, Oliver J. Mc Elvaney, Oisin F. Mc Elvaney, Fiona Boland, Deirdre Hyland, Pierce Geoghegan, Karen Donnelly, Oisin Friel, Ailbhe Cullen, Ann M. Collins, Daniel Fraughen, Ignacio Martin-Loeches, Martina Hennessy, John G. Laffey, Noel G. Mc Elvaney…
    Citation: Trials 2021 22:288
  24. The primary objective is to evaluate the efficacy of an inactivated and aluminium hydroxide adsorbed SARS-CoV-2 vaccine (Sinovac, China) in voluntary participants after 14 days of the second dose against RT-PC...

    Authors: Murat Akova and Serhat Unal
    Citation: Trials 2021 22:276
  25. Severe acute respiratory infection (SARI) caused by the SARS-CoV-2 virus may cause lung failure and the need for mechanical ventilation. Infection with SARS-COV-2 can lead to activation of inflammatory factors...

    Authors: Arash Rahimi, Hamid Reza Samimagham, Mehdi Hassani Azad, Dariush Hooshyar, Mohsen Arabi and Mitra KazemiJahromi
    Citation: Trials 2021 22:271
  26. The primary objective of MATIS is to determine the efficacy of ruxolitinib (RUX) or fostamatinib (FOS) compared to standard of care (SOC) with respect to reducing the proportion of hospitalised patients progre...

    Authors: Nikhil Vergis, Rachel Phillips, Victoria Cornelius, Alexia Katsarou, Taryn Youngstein, Lucy Cook, Michelle Willicombe, Clio Pilay, Tina Shturova, Melanie Almonte, Asad Charania, Richard Turner, Onn Min Kon, Graham Cooke, Mark Thursz, Svetlana Cherlin…
    Citation: Trials 2021 22:270
  27. The COVID-19 related lockdowns and distancing measures have presented families with unprecedented challenges. A UK-wide cohort study tracking changes in families’ mental health since early lockdown (Co-SPACE) ...

    Authors: Katarzyna Kostyrka-Allchorne, Cathy Creswell, Sarah Byford, Crispin Day, Kimberley Goldsmith, Marta Koch, Walter Muruet Gutierrez, Melanie Palmer, Jasmine Raw, Olly Robertson, James Shearer, Adrienne Shum, Petr Slovak, Polly Waite and Edmund J. S. Sonuga-Barke
    Citation: Trials 2021 22:267
  28. To examine the effectiveness of randomising dissemination of the Germ Defence behaviour change website via GP practices across England UK.

    Authors: Jeremy Horwood, Melanie Chalder, Ben Ainsworth, James Denison-Day, Frank de Vocht, Martha M. C. Elwenspoek, Pippa Craggs, Rachel Denholm, Jonathan Sterne, Cathy Rice, Sascha Miller, Beth Stuart, Paul Little, Michael Moore, Merlin Willcox, John Macleod…
    Citation: Trials 2021 22:263
  29. The primary objective is to determine the effect of a daily dose of ivermectin administered in three consecutive days to non-severe COVID-19 patients with no more than 96 hours of symptoms, on the detection of...

    Authors: Patricia J. Garcia, Hansel Mundaca, Cesar Ugarte-Gil, Patricia Leon, German Malaga, Carlos Chaccour and Cesar P. Carcamo
    Citation: Trials 2021 22:262
  30. This study is conducted to investigate efficacy of pomegranate juice on inflammatory biomarkers, C-reactive protein (CRP), interleukin 6(IL-6), erythrocyte sedimentation rate (ESR) and complete blood count (CB...

    Authors: Mojtaba Yousefi, Mohammadreza Sadriirani, Azizollah PourMahmoudi, Sara Mahmoodi, Bahar Samimi, Mahboobe Hosseinikia, Zaker Saeedinezhad and Seyed Bahman Panahande
    Citation: Trials 2021 22:246
  31. These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in addition to supportive self-care (SSC) compared with SSC alone in outpatients with mild to moderate coronavirus disease 2019 (COV...

    Authors: John P. Haran, Jose C. Pinero, Yan Zheng, Norma Alonzo Palma and Mark Wingertzahn
    Citation: Trials 2021 22:245
  32. The main goal of the COVIDENZA trial is to evaluate if inhibition of testosterone signalling by enzalutamide can improve the outcome of patients hospitalised for COVID-19. The hypothesis is based on the observ...

    Authors: Karin Welén, Anna K Överby, Clas Ahlm, Eva Freyhult, David Robinsson, Anna Jonsson Henningsson, Johan Stranne, Daniel Bremell, Martin Angelin, Elisabeth Lindquist, Robert Buckland, Camilla Thellenberg Carlsson, Karlis Pauksens, Anna Bill-Axelsson, Olof Akre, Cecilia Ryden…
    Citation: Trials 2021 22:209
  33. To determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to standard care in hospitalized patients admitted...

    Authors: Michelle Sholzberg, Grace H. Tang, Elnara Negri, Hassan Rahhal, Lisa Baumann Kreuziger, Carlos E. Pompilio, Paula James, Michael Fralick, Musaad AlHamzah, Faris Alomran, Eric Tseng, Gloria Lim, David Lillicrap, Marc Carrier, Fionnuala Ní Áinle, Andrew Beckett…
    Citation: Trials 2021 22:202
  34. Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach. Polyclonal neutralizing antibodies offers many advantages...

    Authors: Benjamin Gaborit, Bernard Vanhove, Marie-Anne Vibet, Aurélie Le Thuaut, Karine Lacombe, Vincent Dubee, Florence Ader, Virginie Ferre, Eric Vicaut, Jéremie Orain, Morgane Le Bras, Anne Omnes, Laetitia Berly, Alexandra Jobert, Pascale Morineau-Le Houssine, Karine Botturi…
    Citation: Trials 2021 22:199
  35. The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is assoc...

    Authors: Li-An K. Brown, Nick Freemantle, Judy Breuer, Hakim-Moulay Dehbi, Kashfia Chowdhury, Gemma Jones, Felicia Ikeji, Amalia Ndoutoumou, Krishneya Santhirakumar, Nicky Longley, Anna M. Checkley, Joseph F. Standing and David M. Lowe
    Citation: Trials 2021 22:193
  36. The primary objective of this study is to test the hypothesis that administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19. The...

    Authors: Jan Maláska, Jan Stašek, František Duška, Martin Balík, Jan Máca, Jan Hruda, Tomáš Vymazal, Olga Klementová, Jan Zatloukal, Tomáš Gabrhelík, Pavel Novotný, Regina Demlová, Jana Kubátová, Jana Vinklerová, Adam Svobodník, Milan Kratochvíl…
    Citation: Trials 2021 22:172

    The Update to this article has been published in Trials 2022 23:35

  37. To investigate if traditional Chinese medicine (TCM) auricular point acupressure (APA) can alleviate and (or) reduce the pain (including injection site pain, headache, other muscle and joint pain), fatigue, an...

    Authors: Qinwei Fu, Hui Xie, Li Zhou, Xinrong Li, Yang Liu, Min Liu, Chaoyu Wang, Xiaocen Wang, Zhiqiao Wang, Jinfan Tang, Huan Xiao, Zhiyong Xiao, Jing Zhou, Chengzhi Feng, Li Wang, Zhimin Ao…
    Citation: Trials 2021 22:162

    The Update to this article has been published in Trials 2021 22:857

  38. The main objective of this study is to evaluate the effect of intravenous lidocaine on gas exchange and inflammation in acute respiratory distress syndrome due or not to Covid-19 pneumonia.

    Authors: Marie Muller, François Lefebvre, Marie-Line Harlay, Ludovic Glady, Guillaume Becker, Charlotte Muller, Ouafaa Aberkane, Mira Tawk, Madoé Julians, Arnaud Romoli, Stéphane Hecketsweiler, Francis Schneider, Julien Pottecher and Thiên-Nga Chamaraux-Tran
    Citation: Trials 2021 22:131
  39. The primary objectives of the study are to determine the effectiveness of the Kaba Sura Kudineer (KSK) & Nilavembu Kudineer (NVK) along with standard Allopathy Treatment to compared with Placebo (Decaffeinated...

    Authors: Anurag Srivastava, Manickavasagam Rengaraju, Saurabh Srivastava, Vimal Narayan, Vivek Gupta and Rashmi Upadhayay
    Citation: Trials 2021 22:130
  40. The objective of the study is to measure the efficacy of ionic-iodine polymer complex [1] for clinical and radiological improvement in coronavirus disease 2019 (COVID-19) patients.

    Authors: Sohaib Ashraf, Shoaib Ashraf, Moneeb Ashraf, Muhammad Ahmad Imran, Larab Kalsoom, Uzma Nasim Siddiqui, Iqra Farooq, Muhammad Ghufran, Romaisa Arshad Khokhar, Muhammad Kiwan Akram, Iqra Shahid, Muhammad Sohaib Ur Rehman, Rutaba Akmal, Arbaz Tahir, Ayesha Zahid, Sidra Ashraf…
    Citation: Trials 2021 22:127

    The Update to this article has been published in Trials 2022 23:58

  41. The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory st...

    Authors: Iwein Gyselinck, Laurens Liesenborghs, Ewout Landeloos, Ann Belmans, Geert Verbeke, Peter Verhamme, Robin Vos and W. Janssens
    Citation: Trials 2021 22:126

    The Correction to this article has been published in Trials 2021 22:187

  42. Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcri...

    Authors: G. Moreno-González, A. Mussetti, A. Albasanz-Puig, I. Salvador, A. Sureda, C. Gudiol, R. Salazar, M. Marin, M. Garcia, V. Navarro, I. de la Haba Vaca, E. Coma, G. Sanz-Linares, X. Dura, S. Fontanals, G. Serrano…
    Citation: Trials 2021 22:116
  43. The aim of the RAAS-COVID-19 randomized control trial is to evaluate whether an upfront strategy of temporary discontinuation of renin angiotensin aldosterone system (RAAS) inhibition versus continuation of RA...

    Authors: Mona Aflaki, Alexandria Flannery, João Pedro Ferreira, Matthew Pellan Cheng, Nadine Kronfli, Ariane Marelli, Faiez Zannad, James Brophy, Jon Afillalo, Thao Huynh, Nadia Giannetti, Amal Bessissow, Justin A. Ezekowitz, Renato D. Lopes, Andrew P. Ambrosy, Morgan Craig…
    Citation: Trials 2021 22:115
  44. To evaluate whether a single high dose of oral cholecalciferol improves the respiratory outcomes as compared with placebo among adults COVID-19 patients at moderate risk of clinical complications.

    Authors: Javier Mariani, Carlos Tajer, Laura Antonietti, Felipe Inserra, León Ferder and Walter Manucha
    Citation: Trials 2021 22:111
  45. To investigate the effectiveness and safety of homeopathic medicine Natrum muriaticum (LM2) for mild cases of COVID-19 in Primary Health Care.

    Authors: Ubiratan Cardinalli Adler, Maristela Schiabel Adler, Livia Mitchiguian Hotta, Ana Elisa Madureira Padula, Amarilys de Toledo Cesar, José Nelson Martins Diniz, Crislaine Aparecida Antonio Mestre, Katia Regina Spiller, Lidiamara Soares, Helen de Freitas Santos and Edson Zangiacomi Martinez
    Citation: Trials 2021 22:109
  46. COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or ther...

    Authors: Elena Diago-Sempere, José Luis Bueno, Aránzazu Sancho-López, Elena Múñez Rubio, Ferrán Torres, Rosa Malo de Molina, Ana Fernández-Cruz, Isabel Salcedo de Diego, Ana Velasco-Iglesias, Concepción Payares-Herrera, Inmaculada Casas Flecha, Cristina Avendaño-Solà, Rafael Duarte Palomino, Antonio Ramos-Martínez and Belén Ruiz-Antorán
    Citation: Trials 2021 22:70
  47. Basic and clinical studies have shown that magnesium sulphate ameliorates lung injury and controls asthma attacks by anti-inflammatory and bronchodilatory effects. Both intravenous and inhaled magnesium sulpha...

    Authors: Guitti Pourdowlat, Seyed Ruhollah Mousavinasab, Behrooz Farzanegan, Alireza Kashefizadeh, Zohreh Akhoundi Meybodi, Maedeh Jafarzadeh and Shadi Baniasadi
    Citation: Trials 2021 22:60
  48. The primary objective of this study is to evaluate the therapeutic potential of hydroxychloroquine (HCQ) in the treatment of adult patients with PCR-confirmed Covid-19 infection in a primary open-care setting,...

    Authors: Petri J. Vainio, Pauliina Hietasalo, Anna-Liisa Koivisto, Susanna Kääriäinen, Jari Turunen, Mika Virtala, Jouni Vuorinen and Mika Scheinin
    Citation: Trials 2021 22:44